Based in Japan and India. Has led to 1 successful fundraise in Japan. Been working the space of Venture Capital and Private Equity for the last 3 years.

This latest round is led by New Enterprise Associates NEA with participation from existing investors Domain Associates who led the Company’s Series A round in , and Okapi Ventures

The funding will be used to fuel development and establish the commercial infrastructure for ChromaCode’s High-Definition Polymerase Chain Reaction technology HDPCR This software and assay technology leverages existing real-time PCR instruments and uses digital signal processing to dramatically improve molecular analysis

The company also appointed co-founder Alex Dickinson Ph D , as Executive Chairman Dr Dickinson joins the company from Illumina where he was senior vice president of strategic initiatives and had prior responsibility for Illumina’s cloud genomics and PCR initiatives NEA Partner Justin Klein M D will be joining the Board of Directors

At NEA we see emerging synergies in information technology and healthcare two of our largest investment areas said NEA’s Justin Klein ChromaCode has strategically positioned itself very well at the crossroads of these two sectors Their insightful application of digital signal processing to extract heretofore untapped information from clinical testing instruments has immense potential Their strategy has the unique ability to simultaneously improve clinical data analysis and reduce healthcare costs ”

Jim Blair Ph D , from Domain Associates added We were intrigued by the ChromaCode technology when it emerged from Caltech two years ago and have seen the team make rapid progress over the past eighteen months Their proprietary solution has the ability to dramatically improve the efficiency and comprehensiveness of molecular diagnostics testing and to do so in a massively scalable way ”

Next-generation sequencing NGS)-based research has delivered a vast array of genetic markers for a multitude of diseases However the high cost complexity and scarcity of NGS has limited the clinical impact of this work said Alex Dickinson ChromaCode’s new executive chairman ChromaCode’s HDPCR enables multiplexed tests on the qPCR instruments that are used every day in all the world’s molecular diagnostic labs enabling universal access to leading-edge diagnostics I’m thrilled to be joining the team to pursue this vision ”

We’re excited to have Justin join the Board and are very enthusiastic about Alex accepting a broader role as executive chair We’re confident this will be a significant catalyst to achieving our strategic ambitions noted ChromaCode’s CEO Greg Gosch

About ChromaCode

ChromaCode is a molecular diagnostics company with a bioinformatics focus and pedigree from Illumina Google[x Luminex and Caltech We leverage patented mathematical methods and algorithmic enhancements to enrich signal processing from the most popular life science instrumentation We are using this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’s gold-standard biochemical assays at a very low cost www chromacode com

About New Enterprise Associates
New Enterprise Associates Inc NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages sectors and geographies With nearly 17 billion in cumulative committed capital since inception NEA invests in technology and healthcare companies at all stages in a company’s lifecycle from seed stage through IPO The firm’s long track record of successful investing includes more than 200 portfolio company IPOs and more than 320 acquisitions www nea com

About Domain Associates
Founded in , Domain was one of the first venture capital firms to exclusively invest in the life sciences sector Today with more than $2 7 billion in capital raised Domain has been a trusted partner in life sciences investing helping more than 260 companies develop novel medical products to advance human health www domainvc com

About Okapi Ventures
Founded in , Okapi Venture Capital invests in seed and early stage life sciences and information technology companies The fund has a southern California and Orange County focus and currently has 46 million under management www okapivc com

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/ChromaCode/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co

Leave a Reply

Your email address will not be published. Required fields are marked *